ARS Pharmaceuticals, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving ARS Pharmaceuticals, Inc. now
Current reporting with the operating signal separated from the noise.
ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Provides Commercial and Financial Updates
The story matters when it changes ARS Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call Transcript
Investors are testing whether ARS Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q2 2025 Earnings Call Transcript
Investors are testing whether ARS Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript
Investors are testing whether ARS Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates
Investors are testing whether ARS Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest SPRY filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
ARS Pharmaceuticals, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →